Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
MacLaren DA, Browne RW, Shaw JK, Krishnan Radhakrishnan S, Khare P, España RA, Clark SD. · 2016
Read Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments. by MacLaren DA, Browne RW, Shaw JK, Krishnan Radhakrishnan S, Khare P, España RA, Clark SD. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5089539.txt.
Description
Duncan A. A. MacLaren and six co-authors reported a rat study in eNeuro in 2016. They tested clozapine N-oxide, or CNO, a drug used to switch engineered brain receptors called DREADDs on or off. CNO was long treated as inert, yet the body can convert it into clozapine, an active drug.
In male Long-Evans rats, one dose of CNO weakened the startle reflex but left a measure of sensory gating unchanged. Higher doses did not change movement on their own, yet one dose blunted the extra movement caused by amphetamine and cut the related rise in dopamine. Blood tests found clozapine after CNO dosing, so the group urges every DREADD study to include animals given CNO without the receptors.
Catalog record
| CREATOR | MacLaren DA, Browne RW, Shaw JK, Krishnan Radhakrishnan S, Khare P, España RA, Clark SD. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |